Biomarck Pharmaceuticals

Biomarck Pharmaceuticals, Ltd. is a clinical stage biotechnology company focused on treating patients with inflammatory and immunological diseases, using the company's platform of patent-protected peptides that have been developed to inhibit MARCKS. As a critical component of the inflammatory process, MARCKS is responsible for neutrophil aggregatio... n at the site of inflammation and cytokine release. Inhibiting MARCKS with the company's peptides reduces the adverse effects of inflammation, including acute respiratory distress syndrome (ARDS) and cytokine storm. Phase 2 trials have been completed with the company's lead peptide, BIO-11006, in ARDS, chronic obstructive pulmonary disease (COPD), and non-small cell lung cancer (NSCLC), supporting safety and efficacy in these three potential indications. In oncology, inhibiting MARCKS with the company's peptides blocks migration of NSCLC cells in vitro and inhibits metastasis in animal models of NSCLC.Read More